ArticleUrology research & practice2025
The Use of Circulating Tumor Cells in T1 Stage Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Article in Urology research & practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Diagnostic and Prognostic Non-Invasive Markers in Bladder Cancer.Diagnostics (Basel, Switzerland) · 2026Review
- Artificial intelligence and multi-omics integration in liquid biopsy for genitourinary cancers: a systematic scoping review.International urology and nephrology · 2026Article
- Liquid biopsy in the clinical management of tumor of urinary system: current status and future developments.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Beyond Visualization: Advanced Imaging, Theragnostics and Biomarker Integration in Urothelial Bladder Cancer.Cancers · 2025Review
- Liquid Biopsy: Current advancements in clinical practice for bladder cancer.The journal of liquid biopsy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-muscle invasive bladder cancer (NMIBC) presents substantial variability in clinical outcomes, especially in high-grade T1 cases, which exhibit high recurrence and progression rates. Circulating tumor cells (CTCs) have emerged as a potential biomarker for cancer prognosis, with evidence linking CTC positivity to poor outcomes in various cancers. In bladder cancer (BC), studies suggest that CTC presence correlates with advanced tumor stage and treatment response, but findings are inconsistent. This study aims to clarify the association between CTC positivity and recurrence and progression to muscle invasiveness in BC. A comprehensive search was conducted using PubMed, SciVerse Scopus, Google Scholar, and the World Health Organization International Clinical Trials Registry Platform databases up to August 2024. This study focuses on assessing the predictive ability of CTCs for NMIBC recurrence and upstaging after transurethral resection of bladder tumor (TURBT). A total of 5 studies were included. Four of the 5 studies found a significant relationship between CTCs and recurrence after TURBT. The hazard ratio (HR) for recurrences was available in 5 studies, and the estimated pooled odds ratio (OR) predicted the value of recurrences for CTC- positive OR = 2.68 (95% CI: 2.11-3.25; P < .001; fixed-effect). Four studies provided data on disease progression from T1 to T2 after TURBT with an overall HR of 3.36 (95% CI: 2.68-3.25). Circulating tumor cells enhance prognostic accuracy and therapeutic strategies in NMIBC, particularly in high-risk cases. Further studies should address molecular subtype stratification and evaluate systemic chemotherapy for CTC-positive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.